| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/11/2001 | CA2421464A1 Combined interferon alfa and liposomal-encapsulated all-trans retinoic acid, including preparation and use |
| 10/11/2001 | CA2405293A1 Topical compositions containing prostaglandin e1 |
| 10/11/2001 | CA2405099A1 Composition and method for promoting oral health |
| 10/11/2001 | CA2404687A1 Sustained release beadlets containing stavudine |
| 10/11/2001 | CA2404369A1 Stable thyroid hormone preparations and method of making same |
| 10/11/2001 | CA2404367A1 Pharmaceutical preparations and their manufacture |
| 10/11/2001 | CA2404298A1 Amiodarone-containing parenteral solution |
| 10/11/2001 | CA2403995A1 Permanent magnet keeper-shield assembly |
| 10/11/2001 | CA2403958A1 Pharmaceutical kit comprising midodrine as an active drug substance |
| 10/11/2001 | CA2403950A1 Treatment of renal disorders |
| 10/11/2001 | CA2403886A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
| 10/11/2001 | CA2403791A1 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
| 10/11/2001 | CA2403661A1 Hydrophilic polymers, pressure sensitive adhesives and coatings |
| 10/11/2001 | CA2402864A1 D and l etherlipid stereoisomers and liposomes |
| 10/11/2001 | CA2401112A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera |
| 10/10/2001 | EP1142903A1 BRAIN CELL OR NERVE CELL-PROTECTIVE AGENTS COMPRISING GINSENOSIDE Rb 1? |
| 10/10/2001 | EP1142878A2 Pharmaceutical compositions comprising moexipril magnesium |
| 10/10/2001 | EP1142590A1 Gene therapy for diabetic ischemic disease |
| 10/10/2001 | EP1142588A1 External preparation |
| 10/10/2001 | EP1142574A1 Pharmaceutical formulations comprising amoxycillin and clavulanate |
| 10/10/2001 | EP1142573A1 Antibacterial medicinal compositions |
| 10/10/2001 | EP1142572A1 Oxetanone-containing preparations for the treatment of intestinal illnesses |
| 10/10/2001 | EP1142571A1 Method to produce solid creatine dosage forms and dosage forms thus obtained |
| 10/10/2001 | EP1142569A2 Coating of small particles |
| 10/10/2001 | EP1142568A1 Pharmaceutical compositions containing cyclosporins |
| 10/10/2001 | EP1142567A2 Production of microspheres |
| 10/10/2001 | EP1142566A1 Compositions for ophtalmic use containing cyclosporin, hyaluronic acid and polysorbate |
| 10/10/2001 | EP1142565A1 Aqueous medicinal compositions |
| 10/10/2001 | EP1141365A1 Method for preparing suspension of stable posiplexes |
| 10/10/2001 | EP1141319A2 Extending graft survival by heme oxygenase-i expression induced immunomodulation |
| 10/10/2001 | EP1141314A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 10/10/2001 | EP1141241A2 Astrocytes, their preparation and uses thereof |
| 10/10/2001 | EP1141235A2 (bifidobacterium) in the treatment of inflammatory disease |
| 10/10/2001 | EP1141232A1 Preservation of sensitive biologicial materials at ambient temperatures by vitrification |
| 10/10/2001 | EP1141079A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties |
| 10/10/2001 | EP1140966A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 10/10/2001 | EP1140965A1 Protonated/acidified nucleic acids and methods of use |
| 10/10/2001 | EP1140960A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 10/10/2001 | EP1140906A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders |
| 10/10/2001 | EP1140876A1 Morpholinone and morpholine derivatives and uses thereof |
| 10/10/2001 | EP1140848A2 Phenethyl-5-bromopyridylthiourea (pbt) and dihydroalkoxybenzyloxopyrimidine (dabo) derivatives exhibiting spermicidal activity |
| 10/10/2001 | EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 10/10/2001 | EP1140479A1 Apparatus and method for manufacturing moulded products |
| 10/10/2001 | EP1140353A1 Preparation of multiwall polymeric microcapsules from hydrophilic polymers |
| 10/10/2001 | EP1140281A1 Thin polymer film drug reservoirs |
| 10/10/2001 | EP1140250A1 Method and device for preparing a medical fluid |
| 10/10/2001 | EP1140242A1 Polymer compositions for intraluminal stent |
| 10/10/2001 | EP1140211A1 Novel ultrasound contrast agents |
| 10/10/2001 | EP1140202A1 Peptidic product, process and composition |
| 10/10/2001 | EP1140199A1 Hyaluronate lyase used for promoting penetration in topical agents |
| 10/10/2001 | EP1140198A1 A composition and method for the enhancement of the efficacy of drugs |
| 10/10/2001 | EP1140197A1 Soluble compositions of toremifene |
| 10/10/2001 | EP1140196A1 Soluble compositions of triphenylethylene antiestrogens |
| 10/10/2001 | EP1140195A1 Oil-in-water emulsion exhibiting a protective action against damages to human organs resulting from peroxidation, and the production and use thereof |
| 10/10/2001 | EP1140170A1 Novel agents and methods for treatment and diagnosis of ocular disorders |
| 10/10/2001 | EP1140169A2 Methods and compositions for decreasing allergic reactions to surface allergens |
| 10/10/2001 | EP1140152A1 Method to produce inactivated w/o emulsion adjuvated vaccines |
| 10/10/2001 | EP1140150A2 Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor |
| 10/10/2001 | EP1140148A1 Shelf-stable formulation of glucagon-like peptide-1 |
| 10/10/2001 | EP1140145A2 Novel exendin agonist formulations and methods of administration thereof |
| 10/10/2001 | EP1140135A1 Cyclosporin solution |
| 10/10/2001 | EP1140133A1 Controlled release formulation comprising gnrh-ii |
| 10/10/2001 | EP1140128A1 Method of using steam ironing of fabrics as a way of causing reduction of physiological and/or subjective reactivity to stress in humans |
| 10/10/2001 | EP1140121A1 Cryogranulation of activated protein c |
| 10/10/2001 | EP1140117A2 Aciclovir compositions containing dimethicone |
| 10/10/2001 | EP1140115A2 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents |
| 10/10/2001 | EP1140114A2 Pharmaceutical formulations |
| 10/10/2001 | EP1140111A1 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 10/10/2001 | EP1140108A1 Method and composition for treatment of female sexual dysfunction |
| 10/10/2001 | EP1140105A1 Controlled release galantamine composition |
| 10/10/2001 | EP1140094A1 Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males |
| 10/10/2001 | EP1140093A2 Compositions having improved delivery of actives |
| 10/10/2001 | EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions |
| 10/10/2001 | EP1140089A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |
| 10/10/2001 | EP1140088A1 Controlled/modified release oral methylphenidate formulations |
| 10/10/2001 | EP1140084A1 Novel formulation |
| 10/10/2001 | EP1140081A2 Improving mental performance by increasing brain insulin sensitivity |
| 10/10/2001 | EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 10/10/2001 | EP1140068A1 Doramectin formulations |
| 10/10/2001 | EP1140064A2 Oral administration of taxoid derivatives |
| 10/10/2001 | EP1140061A2 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 10/10/2001 | EP1140059A2 Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| 10/10/2001 | EP1140057A1 Pharmaceutical composition containing metformin, acarbose or glimepiride and optionally poly-(dimethyl)-siloxane |
| 10/10/2001 | EP1140054A2 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 10/10/2001 | EP1140052A2 Sensitizing agents for the treatment of skin lesions |
| 10/10/2001 | EP1140051A2 Use or tertbutylhydroquinone for lowering blood cholesterol and/or blood triglycerides |
| 10/10/2001 | EP1140050A2 A composition useful to treat periodontal disease |
| 10/10/2001 | EP1140044A2 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION |
| 10/10/2001 | EP1140040A1 Spray-type cosmetic composition and matrix used in said composition for dermal administration |
| 10/10/2001 | EP1140039A1 Transparent transdermal nicotine delivery devices |
| 10/10/2001 | EP1140038A1 Transdermal drug delivery system |
| 10/10/2001 | EP1140037A1 Multiparticulate oral dosage forms |
| 10/10/2001 | EP1140036A2 Novel formulations comprising lipid-regulating agents |
| 10/10/2001 | EP1140035A1 Method for preparing an effervescent granulate comprising iron gluconate, granulate thus obtained and tablets containing the same |
| 10/10/2001 | EP1140034A1 Controlled release formulation of divalproex sodium |
| 10/10/2001 | EP1140033A2 Improved controlled release compositions and method |
| 10/10/2001 | EP1140032A1 A pharmaceutical mixture comprising a profen |
| 10/10/2001 | EP1140031A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient |
| 10/10/2001 | EP1140030A2 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 10/10/2001 | EP1140029A1 Preparation of microparticles having a selected release profile |